louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03648398: Pilot Study of an Online Therapeutic Education Program for Patients With Inflammatory Bowel Disease
Official title: Pilot Study of an Online Therapeutic Education Program for Patients With Inflammatory Bowel Disease
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Crohn's Disease
Ulcerative Colitis
Keywords: Therapeutic education program
Online
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2018-08-27
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: EDUMICILOR is a monocentric prospective pilot study for patients with inflammatory bowel disease (IBD).

During the study, patients will participate in an online therapeutic education program.

They will first have an appointment with a nurse to establish a personalized educational diagnosis. Then they will participate in the online therapeutic education program for about 6 months (depends on the educational needs, expectations and patient's availabilities).

The main objective of this study is to assess the feasibility of an online therapeutic education program for IBD patients.


Eligibility criteria: Inclusion Criteria:

* Male or female (age ≥ 18 years old)
* Patients with established Crohn's disease or ulcerative colitis diagnosis
* Patients who own the equipment to participate in the online therapeutic education program (computer, webcam....)
* French speaking patients
* Patients who cannot attend regular therapeutic education sessions at the hospital
* Patients able to understand the information provided to them and to give written informed consent for the study

Exclusion Criteria:

* Patient who has not given his/her consent to participate

Primary outcomes:
measure: Frequency of participation in the online therapeutic education program
timeFrame: 6 months
Secondary outcomes:
measure: Score of the Crohn and Colitis Knowledge Score
timeFrame: 6 months
measure: Score of the short Inflammatory Bowel Disease Questionnaire (short-IBDQ)
timeFrame: 6 months
measure: Score of the Inflammatory Bowel Disease Disability Index (IBD Disability Index)
timeFrame: 6 months
measure: Score of the Hospital Anxiety and Depression Scale
timeFrame: 6 months
measure: Score of the Girerd Scale
timeFrame: 6 months
measure: Score of a satisfaction survey on the online therapeutic education program
timeFrame: 6 months
Other outcomes:
Locations:
city: Nancy
country: France
facility: CHRU Nancy
Study officials:
affiliation: Central Hospital, Nancy, France
name: Muriel Veltin
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06473298: Role of Light Tracking Intervention in Children With Spastic Hemiplegia
Official title: EFFICACY OF VISUAL LIGHT TRACKING ON CHILDREN WITH SPASTIC HEMIPLEGIA
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Spastic Hemiplegic Cerebral Palsy
Keywords: Visual Light Tracking
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-06-25
Enrollment: 40
Sex: ALL
Minimum age (years): 4
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study aims to investigate the effect of visual light tracking on gait, selective motor control and sensory processing in children with spastic hemiplegic cerebral palsy.


Eligibility criteria: Inclusion Criteria:

* Age ranged from (4-7 years).
* They will be able to walk independently.
* They will have intact auditory pathways.
* They will have intact visual pathways.
* They will have a mild degree of spasticity graded from 1 to 1+ according to the modified Ashworth scale
* They will be mentally stable.

Exclusion Criteria:

* Any other neuromuscular disorders.
* Convulsion.
* Botox injection
* Fixed deformities of lower limbs and spine.
* Selective dorsal rhizotomy (SDR).
* Children with spasticity more than 1+ according to the modified Ashworth scale.
* Children with visual disorders such as squint myopia.
* children with auditory problems.

Primary outcomes:
measure: Effect of Visual light tracking intervention on quality of walking, selective motor control and sensory processing of the study group compared to control group with different intervention.
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo University
Study officials:
References:
Clinical trial NCT00792298: Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)
Official title: A Phase IIb, Multicenter, Randomized, Double-Blind Placebo-Controlled, 2-period Adaptive Crossover Polysomnography Study to Evaluate Safety and Efficacy of MK-4305 in Patients With Primary Insomnia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Primary Insomnia
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2008-11-17
Enrollment: 254
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: A cross-over, polysomnography study to test the safety, tolerability and effectiveness of different doses of suvorexant (MK-4305) in the treatment of patients with primary insomnia.


Eligibility criteria: Inclusion Criteria:

* Has a diagnosis of Primary Insomnia based on sleep history and the investigator's judgment
* Must be willing to stay overnight at a sleep laboratory
* Must be willing to stay in bed for at least 8 hours each night while at the sleep laboratory
* Regular bedtime is between 9 PM and 12 AM (midnight)

Exclusion Criteria:

* Breast feeding, pregnant or planning to become pregnant during the study
* Within the past 6 months before starting the study you have a history of significant cardiovascular disorder such as unstable angina, congestive heart - failure or acute coronary syndrome
* Currently participating or have participated in a study with an investigational compound or device within the last 30 days
* Has traveled across 3 or more time zones in the last 2 weeks or plans on traveling across 3 or more time zones at any time during the study
* Has done shift work within the past 2 weeks
* Has donated blood products within the last 8 weeks
* Has difficulty sleeping due to a medical condition

Primary outcomes:
measure: LS Mean Sleep Efficiency (SE) During Periods 1 and 2
timeFrame: Night 1 and end of Week 4
Secondary outcomes:
measure: LS Mean Wake After Persistent Sleep Onset (WASO) During Periods 1 and 2
timeFrame: Night 1 and end of Week 4
measure: LS Mean Latency to the Onset of Persistent Sleep (LPS) During Periods 1 and 2
timeFrame: Night 1 and end of Week 4
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, Lines C, Roth T, Michelson D. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012 Dec 4;79(23):2265-74. doi: 10.1212/WNL.0b013e31827688ee. Epub 2012 Nov 28.
Clinical trial NCT06677398: Three Debriefing Methods in Virtual Patient Simulation
Official title: Three Debriefing Methods in Virtual Patient Simulation: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Virtual Patient
Debriefing Method
Nursing Student
Keywords: Debriefing
Feedback
Effectiveness
Patient Simulation
Virtual Systems
Nursing Students
Lead sponsor: Saglik Bilimleri Universitesi Gulhane Tip Fakultesi
Sponsor class: OTHER
First posted: 2024-11-06
Enrollment: 109
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Parallel group-randomized trial
Primary purpose: OTHER

Brief summary: In simulation-based training, the debriefing session is considered a cornerstone of learning. Therefore, this study aims to compare two different methods of debriefing sessions.


Eligibility criteria: Inclusion Criteria:

* Being 4th grade nursing student at a nursing faculty

Exclusion Criteria:

* Not having participated in simulation before and not having practiced with a virtual patient.

Primary outcomes:
measure: Hypothesis 1
timeFrame: 1 week
measure: Hypothesis 2
timeFrame: 1 week
measure: Hypothesis 3
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: University of Health Sciences Turkey, Gulhane Faculty of Nursing
state: Etlik
Study officials:
References:
citation: Dreifuerst, K.T., 2015. Getting started with debriefing for meaningful learning. Clin Simul Nurs 11, 268-275. https://doi.org/10.1016/j.ecns.2015.01.005
citation: Decker, S., Alinier, G., Crawford, S.B., Gordon, R.M., Jenkins, D., Wilson, C., 2021. Healthcare Simulation Standards of Best PracticeTM The Debriefing Process. Clin Simul Nurs 58, 27-32. https://doi.org/10.1016/j.ecns.2021.08.011
citation: Cheng A, Kessler D, Mackinnon R, Chang TP, Nadkarni VM, Hunt EA, Duval-Arnould J, Lin Y, Cook DA, Pusic M, Hui J, Moher D, Egger M, Auerbach M; International Network for Simulation-based Pediatric Innovation, Research, and Education (INSPIRE) Reporting Guidelines Investigators. Reporting guidelines for health care simulation research: extensions to the CONSORT and STROBE statements. Adv Simul (Lond). 2016 Jul 25;1:25. doi: 10.1186/s41077-016-0025-y. eCollection 2016.
Clinical trial NCT04077398: Volume vs Concentration: Quadratus Lumborum Blocks With High Volume/Low Concentration or Low Volume/ High Concentration in Nephrectomies
Official title: Volume Versus Concentration: a Prospective, Double Blind, Parallel Study to Compare the Clinical Effectiveness of Bilateral Quadratus Lumborum Blocks Using High Volume/Low Concentration or Low Volume/ High Concentration Local Anesthetic in Nephrectomies
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Analgesia
Postoperative Pain
Block
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
First posted: 2019-09-04
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The study will be conducted as a prospective, randomized, double blinded, parallel trial at the University of Pittsburgh Medical Center (UPMC) Shadyside Hospital.
Primary purpose: TREATMENT

Brief summary: The quadratus lumborum has since 2016 become standard of care for abdominal and retroperitoneal surgeries at UPMC-Shadyside Hospital, replacing paravertebral blocks, and as part of a broader multimodal analgesia institutional Enhanced Recovery After surgery protocol. Since the first description of this technique, several approaches to and anatomic targets within the quadratus lumborum plane have been described although their mechanism of action, spread, and relative clinical effectiveness remain areas of some debate. What is proposed here is to investigate the relative clinical effectiveness of the relationship high volume/low concentration of local anesthetic or low volume/ high concentration of local anesthetic.


Eligibility criteria: Inclusion Criteria:

1. Patients 18-90 years old
2. Patients undergoing nephrectomy
3. Body Mass Index 19-36
4. Male and Female
5. All races
6. American Society of Anesthesiologist scale I, II, III

Exclusion Criteria:

1. Patient refusal
2. Pregnancy
3. Non-English speaking or inability to participate in the study
4. Patients with coagulopathy or With International Normalized Ratio \>1,5 the day of the surgery.
5. Chronic steroid use
6. Chronic pain
7. Chronic opiate use

Primary outcomes:
measure: pain control over the next 72 hours after surgery: Visual analogue scale
timeFrame: 72 hours
Secondary outcomes:
measure: opioid consumption during the first 72 hours
timeFrame: 72 hours
measure: time of the first opioid consumption after surgery
timeFrame: 24 hours
measure: 100 feet walking
timeFrame: 48 hours
measure: presence or absence of muscular weakness after Quadratus lumborum type 2 block
timeFrame: 24 hours
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: UPMC shadyside hospital
state: Pennsylvania
Study officials:
References:
citation: Murouchi T, Iwasaki S, Yamakage M. Quadratus Lumborum Block: Analgesic Effects and Chronological Ropivacaine Concentrations After Laparoscopic Surgery. Reg Anesth Pain Med. 2016 Mar-Apr;41(2):146-50. doi: 10.1097/AAP.0000000000000349.
Clinical trial NCT02713698: Propofol Pharmacokinetics and Pharmacodynamics Modelling
Official title: Modelling Propofol Pharmacokinetics and Pharmacodynamics During an Intravenous Anaesthesia Guided by the Bispectral Index (BIS)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Intravenous Anesthetic Agent Overdose
Keywords: Anaesthetics
Intravenous
Propofol
Pharmacokinetics
Pharmacodynamics
Propofol pharmacokinetic-pharmacodynamic model
Lead sponsor: Centro Hospitalar do Porto
Sponsor class: OTHER
First posted: 2016-03-21
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Inpatient care at Centro Hospitalar do Porto

Brief summary: The main purpose of this research is to develop a population pharmacokinetic and pharmacodynamic model of Propofol when used for induction and maintenance of anaesthesia, using BIS as a pharmacodynamic endpoint.

A covariate analysis will be performed in order to account for variability in pharmacokinetic and pharmacodynamic parameters. The influence of age and obesity on propofol pharmacokinetic parameters will be particularly addressed.


Eligibility criteria: Inclusion Criteria:

* Adult patients admitted for nose or ear surgery, bariatric surgery or urgent orthopaedic surgery.

Exclusion Criteria:

* Severe hepatic or renal insufficiency;
* Significant haemodynamic instability previous to the surgery;
* Allergy to eggs or propofol at the time of enrolment;
* Predictive criteria for difficult airway management.

Primary outcomes:
measure: Plasma Propofol Concentration (mcg/mL)
timeFrame: up to 2 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Porto
country: Portugal
facility: Centro Hospitalar do Porto
Study officials:
References:
citation: Araujo AM, Machado HS, Falcao AC, Soares-da-Silva P. Bioelectrical impedance analysis of body composition for the anesthetic induction dose of propofol in older patients. BMC Anesthesiol. 2019 Oct 11;19(1):180. doi: 10.1186/s12871-019-0856-x.
Clinical trial NCT00221598: Effect of Dialysate Temperature on Haemodynamic Stability and Haemodialysis Efficiency
Official title: Effect of Dialysate Temperature on Haemodynamic Stability and Haemodialysis Efficiency
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Renal Failure
Chronic Renal Failure
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
First posted: 2005-09-22
Enrollment: 10
Sex: ALL
Minimum age (years): 21
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Comparison between dialysate temperatures on haemodynamic stability and haemodialysis efficiency.

Detailed description: Comparison of 4 different dialysate temperatures for haemodialysis of patients with chronic renal failure.

Comparison of 3 different dialysate temperatures for haemodialysis of patients with acute renal failure.

Investigation of the efficiency of haemodialysis of patients with acute renal failure

Eligibility criteria: Inclusion Criteria:

* Chronic renal failure
* Acute renal failure
* Aged between 21-90 years

Exclusion Criteria:

-

Primary outcomes:
measure: Haemodynamic stability and tolerance
timeFrame: t0
Secondary outcomes:
Other outcomes:
Locations:
city: Ghent
country: Belgium
facility: University Hospital Ghent
Study officials:
affiliation: University Hospital, Ghent
name: Annemieke Dhondt, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04624698: iStent Inject New Enrollment Post-Approval Study
Official title: iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Glaucoma, Open-Angle
Glaucoma
Lead sponsor: Glaukos Corporation
Sponsor class: INDUSTRY
First posted: 2020-11-12
Enrollment: 358
Sex: ALL
Minimum age (years): 22
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Study to evaluate the rate of clinically relevant complications associated with iStent inject placement in the post-market setting.

Detailed description: To evaluate the rate of clinically relevant complications associated with iStent inject placement and stability, as determined at 36 months in the postmarket setting.

Eligibility criteria: Inclusion Criteria:

1. Male or female ≥ 22 years of age
2. Mild to moderate primary open-angle glaucoma
3. Scheduled to undergo cataract surgery
4. Able and willing to attend scheduled follow-up exams for three years postoperatively
5. Able and willing to provide written informed consent on the IRB approved Informed Consent Form

   Operative Inclusion Criterion:
6. Successful, uncomplicated cataract surgery

Exclusion Criteria:

1. Angle closure glaucoma
2. Traumatic, malignant, uveitic, or neovascular glaucoma or discernible congenital anomalies of the anterior chamber angle
3. Retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure

Primary outcomes:
measure: iStent inject placement and stability
timeFrame: 36 Months
Secondary outcomes:
measure: Sight-threatening adverse events
timeFrame: 36 Months
Other outcomes:
measure: Other adverse events
timeFrame: 36 Months
Locations:
city: Phoenix
country: United States
facility: Eye Doctors of Arizona, PLLC
state: Arizona
city: Torrance
country: United States
facility: Wolstan and Goldberg Eye Associates
state: California
city: Dallas
country: United States
facility: Glaucoma Associates of Texas
state: Texas
Study officials:
References:
Clinical trial NCT03593798: Lifestyle Intervention and Physical Capacity in Patients With Morbid Obesity
Official title: Lifestyle Intervention and Physical Capacity in Patients With Morbid Obesity
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Physical Capacity
Lead sponsor: Sykehuset i Vestfold HF
Sponsor class: OTHER
Collaborators: name: University college of south-east Norway
First posted: 2018-07-20
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Obese patient seeking lifestyle intervention program

Brief summary: Lifestyle intervention and physical capacity in patients with morbid Obesity (LEICO)

Detailed description: It is still uncertainty about which is the most effective lifestyle treatment to reducing body weight and increased quality of life. Increased physical capacity and muscle mass lead to increased energy expenditure, thus explaining parts of the difference in weight loss achieved after lifestyle treatment. However, literature in this area is limited and need better documentation of how, and to what extent increased physical capacity can affect the effect of lifestyle treatment offered to patients in the health service.

Eligibility criteria: Inclusion Criteria:

* Treatment morbidly obese patients (BMI ≥ 40 kg/m2 or BMI 35 to 39.9 kg/m2 with ≥ 1 co morbidity) attending the Vestfold Hospital Trust.

Exclusion Criteria:

* Uncompensated heart failure
* Recent myocardial infarction or stroke (\<½ years)
* Severe arrhythmia or heart failure
* Unstable angina pectoris
* Renal failure
* Severe eating disorders
* Active substance abuse

Primary outcomes:
measure: Weight change at 1-year follow up
timeFrame: Changes from baseline body weight at 1-year follow up.
measure: Weight change at 12-weeks follow up
timeFrame: Changes from baseline body weight at 12-weeks follow up.
Secondary outcomes:
measure: Physical capacity changes after 12 weeks as assessed by the maximal oxygen uptake test
timeFrame: Changes from baseline physical capacity at 12-weeks follow up.
Other outcomes:
Locations:
city: Bø
country: Norway
facility: Telemark University College
city: Tønsberg
country: Norway
facility: Vestfold Hospital Trust
Study officials:
affiliation: The Hospital of Vestfold
name: Jens Hertel, PhD
role: STUDY_DIRECTOR
References:
citation: Berge J, Storen O, Hertel JK, Gjevestad E, Smastuen MC, Hjelmesaeth J. Associations between cardiorespiratory fitness and weight loss in patients with severe obesity undergoing an intensive lifestyle intervention program: retrospective cohort study. BMC Endocr Disord. 2019 Jul 1;19(1):69. doi: 10.1186/s12902-019-0394-z.
Clinical trial NCT02431598: Eovist vs. Dotarem Healthy Volunteer MRI
Official title: Randomized, Blinded, Placebo-controlled Crossover Study Assessing Association Between Gadolinium-based Contrast Agent Administration and Transient Dyspnea/Arterial Phase Motion Artifact
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Transient Severe Arterial Phase Motion
Lead sponsor: Duke University
Sponsor class: OTHER
Collaborators: name: University of California, San Diego
name: University of Wisconsin, Madison
First posted: 2015-05-01
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to evaluate changes in volunteer breath-holding capacity in response to gadoxetate disodium (Eovist) administration, compared with saline, and gadoterate dimeglumine (Dotarem). Healthy volunteers will be recruited from three study sites. These subjects will be given three, blinded, randomized injections while undergoing an MRI of their liver and holding their breath. During the scan, the subjects' oxygen saturation and heart rate will be closely monitored. Following the scan, the subjects will complete a questionnaire regarding the breath hold.


Eligibility criteria: Inclusion Criteria:

- normal renal function (serum eGFR \>60)

Exclusion Criteria:

* renal impairment
* allergy to gadolinium-based contrast
* metallic implanted devices
* claustrophobia
* pregnant and lactating females

Primary outcomes:
measure: Subject Breath Hold Capacity, as Measured by Number of Seconds a Subject Can Hold His/Her Breath
timeFrame: following contrast administration, up to 5 minutes
measure: Subject-reported Dyspnea, as Measured by Questionnaire Responses
timeFrame: following contrast administration, up to 5 minutes
Secondary outcomes:
measure: O2 Saturation Following Contrast Administration
timeFrame: following contrast administration, up to 5 minutes
measure: Heart Rate Following Contrast Injection
timeFrame: following contrast administration, up to 5 minutes
measure: Percentage of Participants With Transient Severe Motion (TSM) Based on Presence of Motion Artifacts at Arterial Phase Imaging
timeFrame: following contrast administration, up to 5 minutes
measure: Severity of Motion Artifacts at Arterial Phase Imaging, Measured on a 1-5 Scale
timeFrame: following contrast administration, up to 5 minutes
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke Medical Center
state: North Carolina
Study officials:
affiliation: Duke University
name: Mustafa Bashir, MD
role: PRINCIPAL_INVESTIGATOR
References: